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organs-at-risk toxicity. This study was performed to assess 
the best dosimetric predictor of urethra strictures. 
Materials and Methods: Patients treated between 2001 and 
2013 at a single institution with HDRB were retrospectively 
analysed. The patients were all reviewed 6, 12, 18, 24 
months and then every year until 10 years after the 
treatment and data collected in a database. Clinical, 
demographic, dosimetric and urethral stricture factors were 
captured. We used urethra Dose Volume Histograms (DVH) 
metrics: D10% (Gy), D5%(Gy) and D30%(Gy). We converted 
doses from 3 different fractionation regimes (18 Gy in 3, 19 
Gy in 2 and 18 Gy in 2 fractions) into Biological Effective Dose 
(BED) with α/β = 5 Gy. Univariate and Multivariate logistic 
regression were used to evaluate factors predictive of 
urethral stricture after HDRB. 
Results: 
 
We analysed data from 249 patients, with a median follow-up 
of 7 years (1.4- 13.4 years). Urethra strictures were present 
in 25/249 (10%) patients, and the median time to onset 
stricture was about 1.5 years (1 month-7 years). 
On univariate analysis, BED10%(Gy) (OR = 1.05, p= 0.01), 
BED30%(Gy) (OR = 1.05, p= 0.02), and BED5%(Gy) (OR=1.05, 
p= 0.01) were significantly correlated to urethra stricture. 
The AUC of the resulting model was 0.62 in all cases, 
however calibration was always suboptimal. Calibration 
showed improvement when the dosimetric factors were 
associated to clinical factors despite their lower significance, 
such as use of neoadjuvant androgen deprivation (OR=0.5, 
protective factor) which was present in 232 patients (Figure 
1).  
Conclusions: Urethra DVH metrics are related to stricture, 
particularly the dose to small urethra volumes (D10%). 
However androgen deprivation acts as an important dose 
response modifier, pointing out the importance of integrating 
dosimetric and clinical information in order to have a better 
identification of the subgroup of patients at high risk of 
developing severe urinary toxicity after HDRB. 
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Purpose/Objective: To demonstrate the feasibility, safety 
and effectiveness of dose escalation to Dominant 
Intraprostatic Lesion (DIL) as defined on multiparametric MRI 
(mpMRI) with Real-Time MRI-TRUS fusion High-Dose-Rate 
(HDR) Brachytherapy 
Materials and Methods: 15 patients with intermediate-high 
risk Prostate cancer and visible dominant intra-prostatic 
nodule on mpMRI have been treated prospectively. The 
treatment consisted of combined MRI-TRUS fusion HDR-
brachytherapy (1 fraction of 1500 cGy) and Hypofractionated 
external beam (3750 cGy in 15 fractions) (BED: 265Gy). 
Prostate gland, DILs and Organs at risk (OARs) were 
delineated on MRI dataset, MRI-TRUS fusion performed and 
contoured structures transferred to the US dataset. 
The homogeneity parameters used for optimization aim were 
prostate-V100 > 98%, V150 of 25-33%, V200 < 8%, urethral 
Dmax < 115% and rectal D1cc < 70% of prescribed dose. 
Within these constraints, a dose of 1875 Gy was delivered to 
at least 98% of the DIL volume (V125%>98%)(BED: 351Gy) 
Results: Median age was 70 years, median prostate volume 
was 23.8 cc, median number of needles was 16 (13-18). Dose 
escalation to DIL was feasible in 14/15 patients (93%) without 
violating dosimetric constraints and 1 patient presented a 
minimal deviation of dosimetric restrictions. Median prostate 
V100, V150 and V200 were 98.2, 30.6 and 7.4% respectively. 
Median urethral Dmax was 114.1%, median rectal D1cc was 
62.8%. Median V100, V125, V150 and V200 to DIL were: 100, 
99, 78.5 and 20% respectively. 
With a median follow-up of 10 months (range 9-16), none of 
the patients developed acute urinary retention, only 2 
patients presented acute GU grade 2 toxicity, none of the 
patients developed chronic grade ≥2 toxicity. All patients 
returned to the pre-treatment IPSS level after 2 months of 
follow-up. 
In addition to standard PSA follow-up, response has been 
assessed by mpMRI at 12 months. All patients evaluated with 
MRI presented a complete response based on functional 
parameters. 
Conclusions: This study demonstrates that dose escalation to 
DIL with MRI/TRUS fusion guided HDR brachytherapy is 
feasible, longer follow-up will demonstrate the safety and 
efficacy of this procedure. 
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Purpose/Objective: External Beam Radiotherapy (EBRT) is 
considered the standard practice for localized prostate 
cancer. Although this, local relapses are not negligible and 
the ideal salvage treatment is not well-defined. We report 
our outcomes in terms of efficacy and safety of Salvage High-
Dose-Rate Brachytherapy (HDRB) for locally recurrent 
prostate cancer after definitive radiation therapy (RT). 
Materials and Methods: From august 2004 to July 2014 we 
retrospectively analyzed 60 patients (pts) undergoing HDR-BT 
after pathologic confirmation of locally recurrent disease. 
The median age at recurrence was 66 years (55-77) and, the 
median PSA was 4’13ng/ml (1’27-17). Gleason score and T 
scale were 7 and T2, respectively. Prescribed total dose was 
38Gy. Pts received 4 fractions of 9’5Gy with 2 implants 
separated 2 weeks. The 6% of pts received neoadjuvant 
hormonotherapy and, 11% received adjuvant hormonal 
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therapy. Biochemical failure (after receiving both EBRT 
and/or BQT) was based on Phoenix definition. Acute and late 
genitourinary and gastrointestinal toxicities were 
documented based on Common Terminology Criteria for 
Adverse Events (v4.0). Median follow-up after HDRB was 36 
months (7-109 months). 
Results: At the time of the study the 3-year biochemical 
relapse-free rate was 58% (74-42, 95% CI). Local relapse was 
13% (23-3, 95% CI). 3-year systemic relapse rate was 7’4% 
(8’12-7’04, 95% CI) and the 3-year overall survival rate was 
91% (101-81, 95% CI). Late genitourinary Grade 3 and 4 were 
8’3% and 3’3%, respectively. Nine patients required urinary 
catheter, 5 patients required transurethral resection and 2 
pts required suprapubic cistostomy. No Grade 3 or 4 rectal 
toxicity were observed in our study. 
Conclusions: Salvage prostate HDRB is an effective modality 
for locally recurrent cancer after EBRT with an acceptable 
late genitourinary toxicity of 8’3%. 
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Purpose/Objective: The dosimetry of 106Ru plaques typically 
relies on one-dimensional dose measurements on the central 
axis of the brachytherapy source. However, to better 
characterize the dosimetric properties and for comprehensive 
quality assurance of different applicator models 
multidimensional measurements are necessary, which in turn 
can be used for treatment planning. In this study 
radiochromic film measurements were performed in multiple 
planes and benchmarked with Monte Carlo (MC) simulations, 
micro-diamond and diode measurements in terms of absolute 
dose rates and relative dose distributions. 
Materials and Methods: Using EBT3 films 2D dose 
distributions of three different applicator models (CCA, CCB 
and COB) were measured parallel to the central axis as well 
as on normal planes in a purpose-built and in-house 
developed polystyrene phantom. Source non-uniformity was 
evaluated in-air using films in a simple setup. All applicators 
were modeled using the MCNP6 MC code. Reference dose 
rates and dose distributions of MC and films were validated 
against BEBIG values and micro-diamond and diode 
measurements performed in a water-scanning phantom. The 
benchmarked dose distributions were superimposed on 
representative tumor geometries of a broad range of clinical 
target sizes. The respective dosimetric margins were 
determined for a given combination of target and applicator 
size in order to assess the applicator types in terms of their 
limits concerning tumor coverage and tumor volume.  
Results: The agreement of absolute dose rates at a reference 
depth of 2 mm on the central axis of the applicator was 
better than 5 % comparing film measurements with respect to 
the manufacturer's data. The source non-uniformity 
evaluation yielded values < 10 %. The MC absolute dose rates 
showed larger deviations with up to 10 % deviations from film 
results. These high differences were close to the plaque's 
surface but quickly vanished for depths > 2-3 mm, depending 
on the applicator model. For the depth-dose profiles the 
measurements yielded a reproducibility (1 SD) < 4 % for all 
investigated applicator types and all detectors. A comparison 
of measured and calculated data using local γ-index criteria 
of 1 mm/5 % showed pass rates > 94 %. Tumor coverage was 
evaluated regarding the dose prescribed to the tumor apex. 
It was found that for a majority of cases the tumor volume is 
either not sufficiently covered by the 100 % prescription 
isodose or does not provide a margin to allow for dosimetric 
uncertainties if the difference between applicator diameter 
and basal diameter ≤ 4 mm. 
Conclusions: Multidimensional film dosimetry for 106Ru eye 
applications was successfully established and validated 
against MC calculations as well as other experimental 
methods. Both absolute and relative dose measurements 
were well within the tolerances given by the manufacturer. 
The multidimensional dosimetric information can be utilized 
in treatment planning.  
   
OC-0092   
DVH-based inverse planning of prostate HDR brachytherapy 
by simulated annealing rapidly gives good solutions 
T.M. Deist1, B.L. Gorissen1 
1Tilburg University, Department of Econometrics and 
Operations Research, Tilburg, The Netherlands  
 
Purpose/Objective: Inverse planning software for HDR 
brachytherapy currently used in hospitals employ dose-based 
penalty functions. The resulting treatment plans may require 
manual a posteriori adjustments to meet clinical criteria. As 
treatment plans are changed intraoperatively after catheter 
insertion, computation speed is a relevant criterion. 
Therefore, new algorithms need to be developed that 
directly and rapidly optimize clinically relevant dose-volume 
histogram (DVH)-criteria. These algorithms rely on expensive 
general purpose solvers. In this work, we propose a local 
search algorithm, DVH-Optimization by Pure Simulated 
Annealing (DOPSA), which is independent of cost-intensive 
general purpose solvers, directly optimizes for clinically 
relevant criteria, and provides high-quality treatment plans 
within seconds. 
Materials and Methods: We have devised a simulated 
annealing-based local search algorithm that maximizes the 
prostate volume receiving the prescribed dose,V100% , while 
strictly complying to imposed DVH-constraints, D10% and Dmax, 
on rectum and urethra. The algorithm's architecture allows 
extensions to more constraints. The computationally most 
constraining step is addressed by efficient large-scale sparse 
matrix multiplication. Constraint satisfaction is 
parsimoniously evaluated and neighborhood searches 
dynamically adjust to local search space characteristics. The 
algorithm is compared to two existing DVH-based inverse 
planning solutions, IPIP by Siauw et al.(2011) and MILP by 
Gorissen et al. (2013), using data of three patients. 
Results: Any solution by the algorithm provides a treatment 
plan which conforms to the imposed DVH-criteria. Based on 
the available data of three patients, the proposed algorithm 
displays advantages over both alternative optimizers: DOPSA 
consistently outperforms IPIP in plan quality at negligible 
differences in speed. MILP takes considerably longer to 
provide plans of comparable quality but, given sufficient 
